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ABSTRACT: Kasabach-Merritt syndrome (KMS) is characterized by a rapidly enlarging 
hemangioma, thrombocytopenia, microangiopathic hemolytic anemia and consumption 
coagulopathy as a result of platelet and red blood cell trapping and activation of clotting 
system within the vasculature of hemangioma. This syndrome is shown to be associated 
with kaposiform hemangioendotheliomas or tufted hemangioma. 
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INTRODUCTION
ᴪ 
 
KMS is a rare disease, usually of infants, in which 
a vascular tumor leads to decreased platelet counts 
and sometimes other bleeding problems which can 
be life-threatening.
1 I t  i s  a l s o  k n o w n  a s  
Hemangioma thrombocytopenia syndrome. It 
carries the names of Dr Haig Haigouni Kasabach 
and Dr Katharine Krom Merritt, the two 
pediatricians who first described the condition in 
1940.
2  The diagnosis is based upon three basic 
findings; enlarging hemangioma, thrombocytopenia 
and consumption coagulopathy. The 
thrombocytopenia and consumption coagulopathy 
is known as Kasabach-Merritt phenomenon.
3 
Untreated Kasabach-Merritt syndrome has a 10-
37% mortality rate.
4  
 
CASE REPORT 
 
I present a case of a 4 month old male child 
admitted to department of Pediatrics for the 
complaints of swelling on right cheek at right 
corner of mouth. This child was a product of full 
term uncomplicated pregnancy and was delivered 
by lower segment cesarean section. There was no 
history of consanguinity. According to the mother, 
there was a bluish purple birth mark of 
approximately 5cm x 5cms at the right corner of 
mouth at birth. This mark progressively increased 
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in size and gradually involved whole right cheek 
with posterior extension up to right ear lobule. 
Because of this swelling the child was not able to 
take feeds for the last few days.  The 
developmental milestones were normal as per age 
and he was on exclusive breast milk feeding. On 
examination it was a pink colored hemangioma of 
approximately 15cm x 15cm in size (Figure 1). 
Because of it, the child was unable to open his 
mouth sufficient for feeding. We started treatment 
with oral prednisolone (2mg/kg/day) but there was 
no reduction in the size of swelling after 2 weeks of 
therapy. During the hospital stay, one morning, the 
child developed bleeding from the local swelling 
site and also multiple petechial spots all over the 
body. So, coagulation profile of the child was 
assessed. The investigations showed platelet count 
- 5000/mm
3, prothrombin - more than 1 min 
(control - 10.9 Seconds) with Prothrombin 
concentration < than 10% (reference range 70 -
130%) and APTT more than 2 minutes (control 
26.05 seconds). Keeping the possibility of 
consumptive coagulopathy in view, the child was 
further investigated and this showed plasma 
fibrinogen less than 50 mg/dl and D-dimer levels 
more than 500 ng/ml. This triad of hemangioma,  
thrombocytopenia and consumption coagulopathy 
led to the diagnosis of KMS.  
To control the life threatening bleeding, the patient 
was given 5 units of platelet transfusions, 1 unit of 
packed red cell transfusions and 2 units of fresh 
frozen plasma transfusions. After the two weeks of 
the conventional steroid with no therapeutic 
benefit, injectable Vincristine was started in dose of Avasthi et al / Vincristine: a new treatment option for Kasabach-Merritt Syndrome 
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0.05 mg/kg/week. At the time of initiation of 
Vincristine treatment, the platelet count was 
9600/mm
3. After 3 weeks of Vincristine, the 
platelet count increased to 1, 06,000/mm
3 along 
with 25% reduction in the size of swelling. 
Vincristine was continued for a total period of 6 
weeks. After starting treatment with Vincristine, no 
further transfusions were required and child started 
breast feeding normally.  At the end of 
chemotherapy by Vincristine for 6 weeks, there 
was a small lesion 6 cm x 4 cms size, which was 
planned for surgery later in life if it increases in 
size at all. The patient was followed till 1 year of 
age; the features of coagulopathy subsided during 
admission and never recurred after discharge and 
tumor size reduced.  
 
 
Figure 1: Hemangioma 
 
DISCUSSION 
 
For the treatment of KMS there are no consensus 
guidelines as it is uncommon and thus no large 
trials are available to guide treatment. Multiple 
modalities have been used by various workers 
including surgical excision (if possible), laser 
photocoagulation, high dose corticosteroids, anti-
neoplastic agents and anti-angiogenic agent such as 
interferon-α. 
On reviewing the literature, corticosteroids are the 
drugs used commonly for treatment, although the 
results were not satisfactory. There is a case report 
of successful treatment of abdominal wall mass 
associated KMS with Vincristine along with 
surgery.
3 In a recently published case series of 4 
cases, the authors recommend that Vincristine 
should be considered early in the management of 
KMS.
5  In another case report, the authors have 
successfully used Vincristine to treat a 1 month old 
infant with KMS.
6 In our case, we were able to treat 
Kasabach Merritt phenomenon along with 
considerable reduction in the size of swelling with 
Vincristine. In all the previous case reports, surgery 
was done in conjunction with treatment with 
Vincristine. We have deferred surgery at present 
and it is planned if on follow up the swelling again 
increases in size. 
In addition to conventional doses, high-dose 
steroids, pulsed or intravenous steroids have also 
been used with variable results. Interferon-α (1-3 
MU/m
2/day) has been also used as initial therapy 
and especially in patients who do not respond to 
corticosteroid therapy. There is a case report of 
treatment of an infiltrating angiolipoma with KMS 
with complete disappearance of mass after 6 
months treatment with interferon-α.
7 Similarly 
there is a case report where after the conventional 
doses and pulsed high doses of 
methylprednisolone, authors have successfully used 
interferon-α in a 1 month old infant with tumor 
regression. Radiotherapy in combination with 
interferon-α can also be used as a treatment 
modality after the failure of conventional steroid.
8 
Intermittent pneumatic compression has also been 
used as a treatment modality to treat angiomatous 
nevus of leg with KMS in a 6 week old infant.
9 
Pentoxifylline and Tranexamic acid have also been 
u s e d  t o  t r e a t  K M S .   K o m i y a m a  e t  a l  h a v e  d o n e  
endovascular treatment which constituted 
transfemoral embolization using polyvinyl alcohol 
particles and resulted in rapid clinical 
improvement.
10 There are some other case reports 
where authors have used Vincristine to treat 
KMS.
11-14 This treatment is used nowadays with 
increasing frequency. There are several case reports 
of successful treatment of KMS with disappearance 
of bleeding and shrinkage of the size of the tumor 
by treatment with Vincristine alone or in 
conjunction with some other agents as given in 
table 1.  
 
CONCLUSION 
 
Hemangioma associated with KMS is a rare entity. 
We found a rapid rise in platelet count following 
Vincristine treatment which was life-saving for the 
infant. Therefore, it is concluded that Vincristine is 
a good treatment modality for KM syndrome 
especially to treat the consumption coagulopathy 
refractory to conventional doses of steroid. In 
addition, Vincristine will help to reduce the size of 
the swelling, which can then be surgically excised. 
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Table 1: Treatment modalities used in conjunction of Vincristine 
 
Studies Age  of 
patient 
No. of 
patient 
Lesion location  Other/ancillary 
treatment 
Outcome 
Hu et al
13 
(1998) 
Six year  1  Right leg  Vincristine 
Actinomycin 
Cyclophosphamide 
9 months 
follow up 
decrease in 
size of tumor 
Komiyama et 
al
10 (2000) 
2 months  1  Cervicofacial- 
Causing airway 
compromise 
Vincristine with 
transfemoral 
embolization 
Rapid clinical 
improvement 
& patency of 
airway 
Haisley-
Royster et 
al
14 
(2002) 
 15  Five-  kaposiform 
hemangioendotheliomas, 
3 tufted angiomas, 1 
both kaposiform 
hemangioendothelioma  
Vincristine  In 13 patients’ 
significant 
decrease in 
size of lesion, 
4 relapsed. 
Thomson et 
al
5 (2007) 
Birth - 11 
months 
4   Vincristine  Regression  of 
mass 
Abbas et al
3 
(2008) 
5 months  1  Abdominal wall mass  Vincristine  with 
surgery 
Excised 
completely 
Hara et al
6 
(2009) 
1month  1  Cutaneous Right axilla  Vincristine  with 
Corticosteroid 
Regression of 
mass 
Lopez et al
11 
(2009) 
Newborn 1  Skin  Vincristine  with 
Ticlopedine 
Progressive 
remission 
Drucker AM 
et al
12 (2009) 
Newborn 1  Right  leg  Vincristine  with 
Corticosteroid 
Tumour 
shrinkage- 1 yr 
of age 
Present 
Study 
4 months  1  Right Cheek  Vincristine  6 weeks follow 
up – decrease 
in tumor size 
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